Acquired angioedema and marginal zone lymphoma.

[1]  G. Schechter,et al.  Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. , 2010, Seminars in hematology.

[2]  L. Quartuccio,et al.  Controversies on Rituximab Therapy in Sjögren Syndrome-Associated Lymphoproliferation , 2010, International journal of rheumatology.

[3]  M. Cicardi,et al.  Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. , 2008, Autoimmunity reviews.

[4]  P. Korkolopoulou,et al.  Rituximab monotherapy is highly effective in splenic marginal zone lymphoma , 2007, Hematological oncology.

[5]  M. Cicardi,et al.  Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management. , 2006, Immunology and allergy clinics of North America.

[6]  M. Levi,et al.  Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. , 2006, The American journal of medicine.

[7]  K. Do,et al.  Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone , 2006, Cancer.

[8]  A. Vissink,et al.  Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. , 2005, Arthritis and rheumatism.

[9]  M. Cicardi,et al.  Autoantibodies and Lymphoproliferative Diseases in Acquired C1-Inhibitor Deficiencies , 2003, Medicine.

[10]  G. Salles,et al.  Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. , 2003, The Lancet. Oncology.

[11]  B. Bain,et al.  Acquired angioedema as the presenting feature of lymphoproliferative disorders of mature B‐lymphocytes , 1993, Cancer.

[12]  J. Fiechtner,et al.  Acquired angioedema, autoimmune hemolytic anemia, and lymphoma: resolution after therapy. , 1980, Clinical Immunology and Immunopathology.

[13]  Kazuhide Ishikura,et al.  Transition of thyroid autoantibodies by rituximab treatment for thyroid MALT lymphoma. , 2011, Endocrine journal.

[14]  Y. Bertrand,et al.  Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. , 2006 .